The Effectiveness and Efficacy of the Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective for Patients With Mental Health Disorders
Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The combination of pharmacotherapy and individual cognitive behavioral therapy in a private practice.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• age 18-65,
• IQ ≥ 80,
• Diagnosis: anxiety disorders, depression, obsessive-compulsive disorders, PTSD, personality disorders, bipolar disorders, schizophrenia and psychotic disorders.
Locations
Other Locations
Greece
Private practice of Dr. S. Rakitzi and Dr. P. Georgila ILISION 34 15771 ATHENS GREECE
RECRUITING
Athens
Contact Information
Primary
Dr. Stavroula Rakitzi, PhD
Stavroula@Rakitzi.onmicrosoft.com
+306989766935
Backup
Dr. Polyxeni Georgila, M. D.
polyxenigeorgila@gmail.com
+306932905259
Time Frame
Start Date: 2025-06-02
Estimated Completion Date: 2027-12-20
Participants
Target number of participants: 40
Treatments
Experimental: Group A
The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by anxiety disorders and depression.~15 patients
Experimental: Group B
The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by PTSD.~8 patients
Experimental: Group C
The combination of pharmacotherapy (anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder.~10 patients
Experimental: Group D
The combination of pharmacotherapy (anxiolytics ((Tavor, clonotril, lexotanil), antidperessants (SSRI, SNRI), mood stabilizers (Lithium, depakine) and antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by bipolar disorders.~15 patients
Experimental: Group E
The combination of pharmacotherapy (antipsychotics (clozapine and atypical antipsychotics)) , anxiolytics (Tavor, clonotril, lexotanil), antidepressants (SSRI, SNRI)) and individual cognitive behavioral psychotherapy by schizophrenia and psychotic disorders.~10 patients
Experimental: Group F
The combination of pharmacotherapy (antidepressants (SSRI, SNRI), anxiolytics (Tavor, clonotril, lexotanil) antipsychotics (clozapine and atypical antipsychotics)) and individual cognitive behavioral psychotherapy by personality disorders.~17 patients (2 narcistic personality disorder, 5 borderline personality disorder, 3 obsessive-compulsive disorder, 4 avoidant personality disorder, 3 depedent personality disorder)
Related Therapeutic Areas
Sponsors
Leads: Rakitzi, Stavroula